Indegene Launches Cortex, a Generative AI Platform for Life Sciences

The platform is designed to enhance medical content generation, expedite regulatory reviews, and integrate AI-driven processes with enterprise-wide systems while ensuring governance and security.

Indegene, a digital-first life sciences commercialization company, has introduced Cortex, a generative AI (GenAI) platform tailored specifically for the life sciences sector.

The platform is designed to enhance medical content generation, expedite regulatory reviews, and integrate AI-driven processes with enterprise-wide systems while ensuring governance and security.

Cortex is engineered to support key life sciences applications, including medical writing, content management, and medical-legal-regulatory (MLR) reviews. The platform leverages Indegene’s domain expertise through advanced knowledge graphs, which structure and contextualize data for AI applications. The system is adaptable to various large language models (LLMs) and evolves with advancements in AI technology.

“Life sciences leaders believe in GenAI’s potential to transform and modernize their commercialization processes,” said Manish Gupta, chairperson and CEO of Indegene. “They also demand an enterprise-grade platform that assures them of the security, governance, scalability, and business value essential to adopting technology across the enterprise. With this GenAI platform, we codify our 25+ years of practitioner experience, letting life sciences leaders make the most of this transformative technology.”

The company highlights that Cortex’s multi-agent orchestration enables AI to be tailored for specific enterprise use cases, ensuring greater accuracy and efficiency in regulatory documentation and compliance tasks.

Indegene’s Cortex has received attention from industry analysts for its role in integrating GenAI into life sciences workflows. HFS Research recognized Indegene as a Horizon 3 OneEcosystem Exponential Leader, citing its application of AI to enhance health outcomes, stakeholder engagement, and cost optimization.

Tarun Mathur, CTO of Indegene, emphasized the adaptability of Cortex to evolving business models and regulatory requirements. “Life sciences leaders demand an AI infrastructure that adapts to new business models, processes, and experiences. Our new GenAI platform empowers them to develop their own intellectual property (IP), leveraging Indegene’s technology and knowledge engineering practices. We look forward to supporting the wide number of use cases they apply this technology to and the value they realize in the process.”

Additionally, Everest Group identified Indegene as a Front-Runner in GenAI adoption for its focus on industry-specific applications and strategic partnerships.